{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:22:27Z","timestamp":1792718547769,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"\n Importance<\/jats:title>\n Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) in patients with advanced NEC of the digestive system.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This open-label phase 3 randomized clinical trial enrolled chemotherapy-naive patients aged 20 to 75 years who had recurrent or unresectable NEC (according to the 2010 World Health Organization classification system) arising from the gastrointestinal tract, hepatobiliary system, or pancreas. Participants were enrolled across 50 institutions in Japan between August 8, 2014, and March 6, 2020.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n In the EP arm, etoposide (100 mg\/m\n 2<\/jats:sup>\n \/d on days 1, 2, and 3) and cisplatin (80 mg\/m\n 2<\/jats:sup>\n \/d on day 1) were administered every 3 weeks. In the IP arm, irinotecan (60 mg\/m\n 2<\/jats:sup>\n \/d on days 1, 8, and 15) and cisplatin (60 mg\/m\n 2<\/jats:sup>\n \/d on day 1) were administered every 4 weeks.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was OS. In total, data from 170 patients were analyzed to detect a hazard ratio (HR) of 0.67 (median OS of 8 and 12 months in inferior and superior arms, respectively) with a 2-sided \u03b1 of 10% and power of 80%. The pathologic findings were centrally reviewed following treatment initiation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 170 patients included (median [range] age, 64 [29-75] years; 117 [68.8%] male), median OS was 12.5 months in the EP arm and 10.9 months in the IP arm (HR, 1.04; 90% CI, 0.79-1.37;\n P<\/jats:italic>\n \u2009=\u2009.80). The median progression-free survival was 5.6 (95% CI, 4.1-6.9) months in the EP arm and 5.1 (95% CI, 3.3-5.7) months in the IP arm (HR, 1.06; 95% CI, 0.78-1.45). A subgroup analysis of OS demonstrated that EP produced more favorable OS in patients with poorly differentiated NEC of pancreatic origin (HR, 4.10; 95% CI, 1.26-13.31). The common grade 3 and 4 adverse events in the EP vs IP arms were neutropenia (75 of 82 [91.5%] patients vs 44 of 82 [53.7%] patients), leukocytopenia (50 of 82 [61.0%] patients vs 25 of 82 [30.5%] patients), and febrile neutropenia (FN) (22 of 82 [26.8%] patients vs 10 of 82 [12.2%] patients). While incidence of FN was initially high in the EP arm, primary prophylactic use of granulocyte colony-stimulating factor effectively reduced the incidence of FN.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this randomized clinical trial demonstrate that both EP and IP remain the standard first-line chemotherapy options. Although AEs were generally manageable, grade 3 and 4 AEs were more common in the EP arm.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n Japan Registry of Clinical Trials:\n jRCTs031180005<\/jats:ext-link>\n ; UMIN Clinical Trials Registry:\n UMIN000014795<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.3395","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T12:01:55Z","timestamp":1660910515000},"page":"1447","source":"Crossref","is-referenced-by-count":111,"title":["Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System"],"prefix":"10.1001","volume":"8","author":[{"given":"Chigusa","family":"Morizane","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[{"name":"Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Nomura","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital, Tokyo, Japan"},{"name":"The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Sekine","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[{"name":"Kyorin University Faculty of Medicine, Mitaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Sato","sequence":"additional","affiliation":[{"name":"Kochi Health Sciences Center, Kochi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Kyorin University Faculty of Medicine, Mitaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Clinical Oncology Group (JCOG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sano","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sadachi","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuya","family":"Iwafuchi","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Kushima","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ohike","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Katsuta","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Okamura","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasyuki","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shirakawa","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisahiro","family":"Matsubara","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kojima","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Sano","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Umemoto","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Miwa","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Shioji","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Asagi","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Fujimori","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kawakami","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Akiyama","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Murakawa","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kondoh","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yabusaki","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsuji","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Maeda","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takushi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Hamakawa","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Fujitani","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Goto","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryouhei","family":"Kawabata","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kakeji","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohta","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Shinohara","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Hirahara","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Tanabe","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oono","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yuasa","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Etoh","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Amanuma","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Nomura","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nagatani","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[{"name":"for the Japan Clinical Oncology Group (JCOG)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi220039r1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"coi220039r2","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/cas.2014.105.issue-9","article-title":"Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.","volume":"105","author":"Yamaguchi","year":"2014","journal-title":"Cancer Sci"},{"issue":"4","key":"coi220039r3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/cncr.v124.4","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases.","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"issue":"16","key":"coi220039r5","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with Grade 3: a Japanese multicenter pancreatic NEN-G3 study.","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi220039r6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/MPA.0000000000000735","article-title":"Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated.","volume":"46","author":"Raj","year":"2017","journal-title":"Pancreas"},{"issue":"6","key":"coi220039r7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s12328-015-0609-4","article-title":"Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate.","volume":"8","author":"Tanaka","year":"2015","journal-title":"Clin J Gastroenterol"},{"issue":"5","key":"coi220039r8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"coi220039r11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas.","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"7","key":"coi220039r12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"coi220039r15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/tca.2017.8.issue-3","article-title":"Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: a network meta-analyses.","volume":"8","author":"Chen","year":"2017","journal-title":"Thorac Cancer"},{"key":"coi220039r16","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.32750","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study.","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"coi220039r17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000338794","article-title":"Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.","volume":"96","author":"Terashima","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"4","key":"coi220039r18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10120-008-0484-5","article-title":"Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.","volume":"11","author":"Ono","year":"2008","journal-title":"Gastric Cancer"},{"issue":"2","key":"coi220039r19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10120-011-0025-5","article-title":"Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.","volume":"14","author":"Okita","year":"2011","journal-title":"Gastric Cancer"},{"issue":"2","key":"coi220039r20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms.","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"issue":"8","key":"coi220039r21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"issue":"10","key":"coi220039r23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/oxfordjournals.annonc.a058729","article-title":"Extrapulmonary small cell carcinoma: a single-institution experience and review of the literature.","volume":"5","author":"Lo Re","year":"1994","journal-title":"Ann Oncol"},{"issue":"6","key":"coi220039r24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/02841860601071893","article-title":"Extrapulmonary small cell carcinoma: single center experience with 61 patients.","volume":"46","author":"Lee","year":"2007","journal-title":"Acta Oncol"},{"issue":"6","key":"coi220039r25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10620-006-8001-3","article-title":"A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.","volume":"51","author":"Kulke","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"7","key":"coi220039r26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000329609","article-title":"Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.","volume":"34","author":"Jin","year":"2011","journal-title":"Onkologie"},{"issue":"4","key":"coi220039r27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jjco\/hyp173","article-title":"Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.","volume":"40","author":"Iwasa","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"coi220039r28","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/cncr.22235","article-title":"Extrapulmonary small cell cancer: a Canadian province\u2019s experience.","volume":"107","author":"Haider","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"coi220039r29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","article-title":"Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.","volume":"92","author":"Fj\u00e4llskog","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"coi220039r30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jjco\/hyn041","article-title":"Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.","volume":"38","author":"Chin","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"coi220039r31","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.2004.09.075","article-title":"Small-cell carcinomas of the gastrointestinal tract: a review.","volume":"22","author":"Brenner","year":"2004","journal-title":"J Clin Oncol"},{"issue":"28","key":"coi220039r32","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update.","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi220039r33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","article-title":"NCCN guidelines insights: hematopoietic growth factors, Version 1.2020.","volume":"18","author":"Becker","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"23","key":"coi220039r34","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"coi220039r35","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"coi220039r4","volume-title":"WHO Classification of Tumours of the Digestive System","author":"Bosman","year":"2010","edition":"4th ed"},{"key":"coi220039r9","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2017","edition":"4th ed"},{"key":"coi220039r10","volume-title":"WHO Classification of Tumours: Digestive System Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2019","edition":"5th ed"},{"key":"coi220039r22","author":"Mani","year":"2008"},{"key":"coi220039r13","unstructured":"NCCN Clinical Practice Guidelines in Oncology: neuroendocrine and adrenal tumors. National Comprehensive Cancer Network. Accessed July 20, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1448."},{"key":"coi220039r14","unstructured":"NCCN Clinical Practice Guidelines in Oncology: small cell lung cancer. National Comprehensive Cancer Network. Accessed July 20, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2795418\/jamaoncology_morizane_2022_oi_220039_1666196317.60766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T11:06:59Z","timestamp":1666264019000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2795418"}},"subtitle":["The TOPIC-NEC Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.3395","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}